Congenital malformation risks following integrase inhibitor use in pregnancy

Utilising data from the Colorado-based Children’s Hospital Immunodeficiency Program (CHIP), a team of researchers have published a retrospective comparative cohort study of pregnancy and fetal outcomes following first trimester integrase inhibitor use (dolutegravir, elvitegravir or raltegravir). The study describes increased risks of congenital anomalies among the first trimester integrase inhibitor exposed in comparison with those born to women with HIV exposed to non-integrase inhibitor use. More information is available here.

Image by Darwin Laganzon from Pixabay